CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS.Master Formulation Development Agreement • March 8th, 2016 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS MASTER FORMULATION DEVELOPMENT AGREEMENT (the "Agreement'') is entered into as of March 12, 2015 (the "Effective Date' ') by and between OAKWOOD LABORATORIES, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146, USA ("Oakwood''),and Edge Therapeutics, Inc., a New Jersey corporation having an address of 200 Connell Drive Suite 1600 Berkeley Heights, NJ 07922 ("Edge'').
